Safety profile of tacrolimus in patients with rheumatoid arthritis

Clinical Rheumatology

Volumn 27, Issue 11, 2008, Pages 1393-1397

  Akimoto, Kimiko ^a   Kusunoki, Yoshie ^a   Nishio, Shinichiro ^a   Takagi, Kenji ^a   Kawai, Shinichi ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Adverse reaction; Disease modifying antirheumatic drug; Gastrointestinal symptoms; Immunosuppressant; Rheumatoid arthritis; Tacrolimus

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; TACROLIMUS;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MEDICAL ASSESSMENT; MEDICAL RECORD REVIEW; MORNING DOSAGE; NAUSEA AND VOMITING; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN PRURITUS; TACHYCARDIA; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

AGED; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 53849127145     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-008-0931-z     Document Type: Article

References (24)

1. O'Dell JR (2005) Rheumatoid arthritis: The clinical picture. In: Koopman WJ, Moreland LW (eds) Arthritis and allied conditions: A textbook of rheumatology. vol. 1. 15th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1165-1194
2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 46:328-346
3. Kino T, Hatanaka H, Miyata S et al (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot 40:1256-1265
4. Kitahara K, Kawai S (2007) Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol 19:238-245
5. Shapiro R, Jordan ML, Scantlebury VP et al (1995) The superiority of tacrolimus in renal transplant recipients - the Pittsburgh experience. Clin Transpl 199-205
6. Testa G, Klintmalm GB (1997) Cyclosporine and tacrolimus: The mainstay of immunosuppressive therapy for solid organ transplantation. Clin Liver Dis 1:417-437
7. Gremillion RB, Posever JO, Manek N et al (1999) Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: Initial experience in 12 patients. J Rheumatol 26:2332-2336
8. Kondo H, Abe T, Hashimoto H et al (2004) Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: A randomized, double blind, placebo controlled dose-finding study. J Rheumatol 31:243-251
9. Kawai S, Hashimoto H, Kondo H et al (2006) Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. J Rheumatol 33:2153-2161
10. Steinbrocker O, Traeger CH, Batterman RC (1949) Therapeutic criteria in rheumatoid arthritis. JAMA 140:659-662
11. Kawai S, Yamamoto K (2006) Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients. Rheumatol (Oxf) 45:441-444
12. Yocum DE, Furst DE, Kaine JL et al (2003) Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: A double-blind trial. Arthritis Rheum 48:3328-3337
13. Itoh Z, Suzuki T, Nakaya M et al (1984) Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut. Antimicrob Agents Chemother 26:863-869
14. Itoh Z, Nakaya M, Suzuki T et al (1984) Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. Am J Physiol 247:688-694
15. Itoh Z, Suzuki T, Nakaya M et al (1985) Structure-activity relation among macrolide antibiotics in initiation of interdigestive migrating contractions in the canine gastrointestinal tract. Am J Physiol 248:320-325
16. Costa A, Alessiani M, De Ponti F et al (1996) Stimulatory effect of FK506 and erythromycin on pig intestinal motility. Transplant Proc 28:2571-2572
17. Maes BD, Vanwalleghem J, Kuypers D et al (1999) Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. Transplantation 68:1482-1485
18. The U.S. Multicenter FK506 Liver Study Group (1994) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331:1110-1115
19. Mayer AD, Dmitrewski J, Squifflet JP et al (1997) Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 64:436-443
20. Mor E, Schwersenz A, Sheiner PA et al (1994) Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. Transplantation 57:1130-1132
21. Astellas Pharma Inc. (2007) Prografâ (tacrolimus) prescribing information in Japan. Astellas Pharma, Tokyo
22. Fisher A, Schwartz M, Mor E et al (1994) Gastrointestinal toxicity associated with FK506 in liver transplant recipients. Transplant Proc 26:3106-3107
23. Ekberg H, Tedesco-Silva H, Demirbas A et al (2007) Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357:2562-2575
24. Pirsch JD, Miller J, Deierhoi MH et al (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 63:977-983